Myc lacks E2F1's ability to suppress skin carcinogenesis

R. J. Rounbehler, R. Schneider-Broussard, C. J. Conti, David G Johnson

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Myc and E2F1 can each stimulate proliferation, induce apoptosis, and contribute to oncogenic transformation. However, only E2F1 has been shown to have a tumor suppressive activity under some conditions. To examine the potential of Myc to suppress tumorigenesis under one of the conditions in which E2F1 functions to suppress tumorigenesis, transgenic mice expressing Myc under the control of a keratin 5 (K5) promoter were generated. Like K5 E2F1 transgenic mice, K5 Myc transgenic mice have hyperplastic and hyperproliferative epidermis and develop spontaneous tumors in the skin and oral epithelium. In addition, K5 Myc and K5 E2F1 transgenic mice both display aberrant, p53-dependent apoptosis in the epidermis. It has been demonstrated that deregulated expression of E2F1 in the epidermis of transgenic mice inhibits tumorigenesis in a two-stage skin carcinogenesis assay. In sharp contrast to those results, deregulated expression of Myc in the epidermis of transgenic mice resulted in an enhanced response to two-stage skin carcinogenesis. We conclude that while Myc and E2F1 have similar proliferative, apoptotic and oncogenic properties in mouse epidermis, Myc lacks E2F1's tumor suppressive property. This suggests that E2F1's unique ability to inhibit skin carcinogenesis is not simply a consequence of promoting p53-dependent apoptosis.

Original languageEnglish (US)
Pages (from-to)5341-5349
Number of pages9
JournalOncogene
Volume20
Issue number38
DOIs
StatePublished - Aug 30 2001

Fingerprint

Keratin-5
Transgenic Mice
Carcinogenesis
Epidermis
Skin
Apoptosis
Neoplasms
Epithelium

Keywords

  • Apoptosis
  • Carcinogenesis
  • Cell cycle
  • E2F1
  • Myc

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Rounbehler, R. J., Schneider-Broussard, R., Conti, C. J., & Johnson, D. G. (2001). Myc lacks E2F1's ability to suppress skin carcinogenesis. Oncogene, 20(38), 5341-5349. https://doi.org/10.1038/sj.onc.1204691

Myc lacks E2F1's ability to suppress skin carcinogenesis. / Rounbehler, R. J.; Schneider-Broussard, R.; Conti, C. J.; Johnson, David G.

In: Oncogene, Vol. 20, No. 38, 30.08.2001, p. 5341-5349.

Research output: Contribution to journalArticle

Rounbehler, RJ, Schneider-Broussard, R, Conti, CJ & Johnson, DG 2001, 'Myc lacks E2F1's ability to suppress skin carcinogenesis', Oncogene, vol. 20, no. 38, pp. 5341-5349. https://doi.org/10.1038/sj.onc.1204691
Rounbehler RJ, Schneider-Broussard R, Conti CJ, Johnson DG. Myc lacks E2F1's ability to suppress skin carcinogenesis. Oncogene. 2001 Aug 30;20(38):5341-5349. https://doi.org/10.1038/sj.onc.1204691
Rounbehler, R. J. ; Schneider-Broussard, R. ; Conti, C. J. ; Johnson, David G. / Myc lacks E2F1's ability to suppress skin carcinogenesis. In: Oncogene. 2001 ; Vol. 20, No. 38. pp. 5341-5349.
@article{9b8f1f091e1f47d3bcb6cf90bef19c40,
title = "Myc lacks E2F1's ability to suppress skin carcinogenesis",
abstract = "Myc and E2F1 can each stimulate proliferation, induce apoptosis, and contribute to oncogenic transformation. However, only E2F1 has been shown to have a tumor suppressive activity under some conditions. To examine the potential of Myc to suppress tumorigenesis under one of the conditions in which E2F1 functions to suppress tumorigenesis, transgenic mice expressing Myc under the control of a keratin 5 (K5) promoter were generated. Like K5 E2F1 transgenic mice, K5 Myc transgenic mice have hyperplastic and hyperproliferative epidermis and develop spontaneous tumors in the skin and oral epithelium. In addition, K5 Myc and K5 E2F1 transgenic mice both display aberrant, p53-dependent apoptosis in the epidermis. It has been demonstrated that deregulated expression of E2F1 in the epidermis of transgenic mice inhibits tumorigenesis in a two-stage skin carcinogenesis assay. In sharp contrast to those results, deregulated expression of Myc in the epidermis of transgenic mice resulted in an enhanced response to two-stage skin carcinogenesis. We conclude that while Myc and E2F1 have similar proliferative, apoptotic and oncogenic properties in mouse epidermis, Myc lacks E2F1's tumor suppressive property. This suggests that E2F1's unique ability to inhibit skin carcinogenesis is not simply a consequence of promoting p53-dependent apoptosis.",
keywords = "Apoptosis, Carcinogenesis, Cell cycle, E2F1, Myc",
author = "Rounbehler, {R. J.} and R. Schneider-Broussard and Conti, {C. J.} and Johnson, {David G}",
year = "2001",
month = "8",
day = "30",
doi = "10.1038/sj.onc.1204691",
language = "English (US)",
volume = "20",
pages = "5341--5349",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "38",

}

TY - JOUR

T1 - Myc lacks E2F1's ability to suppress skin carcinogenesis

AU - Rounbehler, R. J.

AU - Schneider-Broussard, R.

AU - Conti, C. J.

AU - Johnson, David G

PY - 2001/8/30

Y1 - 2001/8/30

N2 - Myc and E2F1 can each stimulate proliferation, induce apoptosis, and contribute to oncogenic transformation. However, only E2F1 has been shown to have a tumor suppressive activity under some conditions. To examine the potential of Myc to suppress tumorigenesis under one of the conditions in which E2F1 functions to suppress tumorigenesis, transgenic mice expressing Myc under the control of a keratin 5 (K5) promoter were generated. Like K5 E2F1 transgenic mice, K5 Myc transgenic mice have hyperplastic and hyperproliferative epidermis and develop spontaneous tumors in the skin and oral epithelium. In addition, K5 Myc and K5 E2F1 transgenic mice both display aberrant, p53-dependent apoptosis in the epidermis. It has been demonstrated that deregulated expression of E2F1 in the epidermis of transgenic mice inhibits tumorigenesis in a two-stage skin carcinogenesis assay. In sharp contrast to those results, deregulated expression of Myc in the epidermis of transgenic mice resulted in an enhanced response to two-stage skin carcinogenesis. We conclude that while Myc and E2F1 have similar proliferative, apoptotic and oncogenic properties in mouse epidermis, Myc lacks E2F1's tumor suppressive property. This suggests that E2F1's unique ability to inhibit skin carcinogenesis is not simply a consequence of promoting p53-dependent apoptosis.

AB - Myc and E2F1 can each stimulate proliferation, induce apoptosis, and contribute to oncogenic transformation. However, only E2F1 has been shown to have a tumor suppressive activity under some conditions. To examine the potential of Myc to suppress tumorigenesis under one of the conditions in which E2F1 functions to suppress tumorigenesis, transgenic mice expressing Myc under the control of a keratin 5 (K5) promoter were generated. Like K5 E2F1 transgenic mice, K5 Myc transgenic mice have hyperplastic and hyperproliferative epidermis and develop spontaneous tumors in the skin and oral epithelium. In addition, K5 Myc and K5 E2F1 transgenic mice both display aberrant, p53-dependent apoptosis in the epidermis. It has been demonstrated that deregulated expression of E2F1 in the epidermis of transgenic mice inhibits tumorigenesis in a two-stage skin carcinogenesis assay. In sharp contrast to those results, deregulated expression of Myc in the epidermis of transgenic mice resulted in an enhanced response to two-stage skin carcinogenesis. We conclude that while Myc and E2F1 have similar proliferative, apoptotic and oncogenic properties in mouse epidermis, Myc lacks E2F1's tumor suppressive property. This suggests that E2F1's unique ability to inhibit skin carcinogenesis is not simply a consequence of promoting p53-dependent apoptosis.

KW - Apoptosis

KW - Carcinogenesis

KW - Cell cycle

KW - E2F1

KW - Myc

UR - http://www.scopus.com/inward/record.url?scp=0035974915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035974915&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1204691

DO - 10.1038/sj.onc.1204691

M3 - Article

C2 - 11536046

AN - SCOPUS:0035974915

VL - 20

SP - 5341

EP - 5349

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 38

ER -